MetaCap

Black Hawk Acquisition (BKHA) vs IN8bio (INAB)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

IN8bio is the larger company by market cap ($8.2 million vs $7.7 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

BKHA-85.77%INAB-45.86%
+4%-43%-90%
Oct 7, 20261 yearNov 20, 2026
BKHA-83.95%INAB-43.43%
+4%-42%-88%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

BKHA versus INAB key metrics
MetricBKHAINAB
Share price$1.85$0.758
Market cap$7.68M$8.19M
1-day change-71.45%-1.86%
YTD return—-67.61%
1-year return—-55.41%
5-year return—-99.63%
P/E ratio (TTM)5.61—
EPS (TTM)$0.33$-1.00
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$1.33M$-19.44M
52-week high$23.00$2.73
52-week low$1.75$0.724
Distance from 52-week high-91.96%-72.23%
Analyst consensus—none
Avg. price target upside—+823.48%
Average volume101.40K120.61K
Shares outstanding4.15M10.81M
Employees—18
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Black Hawk Acquisition

BKHA stock →

Black Hawk Acquisition Corporation is a blank check company focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. The company was incorporated in 2023 and is based in Danville, California.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances)

About IN8bio

INAB stock →

IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell product candidates for the treatment of cancer and autoimmune diseases. Its lead product candidates include INB-400, which is in Phase 2 clinical trial to treat newly diagnosed glioblastoma (GBM); INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of GBM; and INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with hematologic malignancies undergoing hematopoietic stem cell transplantation.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 18 employees

BKHA vs INAB FAQ

Which is bigger, Black Hawk Acquisition or IN8bio?

IN8bio (INAB) is larger, with a market capitalization of $8.19M compared with $7.68M for Black Hawk Acquisition (BKHA).

Are Black Hawk Acquisition and IN8bio in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons